Status:
UNKNOWN
Double Dose Magnesium Sulphate in Moderate-severe Asthma in Paediatrics
Lead Sponsor:
Oman Medical Speciality Board
Conditions:
Asthma in Children
Eligibility:
All Genders
3-13 years
Phase:
PHASE2
PHASE3
Brief Summary
Introduction : . In Oman the prevalence of asthma was estimated to be 7.3% of adults and 12.7% of children . Magnesium sulphate is the second line treatment, many studies had shown that it has benefic...
Detailed Description
Research questions : In children 3 to 13 years of age presenting to the pediatric emergency room with moderate to severe asthma exacerbation, does double dose Magnesium sulfate improve asthma severit...
Eligibility Criteria
Inclusion
- Physican diagnosed of asthma
- Age 3-13 years
- Children presenting with acute moderate- severe asthma (PRAM score ≥ 5)
- Failed to respond to initial treatment of acute asthma
- Not known to have allergy from MgSO4
Exclusion
- Mild exacerbation of asthma (initial PRAM score ≤4)
- Other comorbid present : Significant heart disease , arrhythmias , chronic kidney disease , cystic fibrosis , operated trachea-esophageal fistula , known or operated for vascular ring , trisomy 21
Key Trial Info
Start Date :
August 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04465175
Start Date
August 1 2020
End Date
December 1 2021
Last Update
July 13 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.